This screen identified small molecules that decreased the activity of anti-CD47 (including steroids, retinoids, and anthracyclines) and, importantly, a class of molecules that increased the activity of anti-CD47 in an EGFR-driven NSCLC model. This evidence concerns the gene CD47 and non-small cell lung carcinoma.